Skip to main content

Interpace Diagnostics Plans $3.6M Public Stock Offering

NEW YORK (GenomeWeb) – Interpace Diagnostics Group announced today that it is planning a $3.6 million public offering of common stock.

The company is offering 1.2 million shares of stock at a public offering price of $3 per share. It expects to receive gross proceeds of approximately $3.6 million, before deducting underwriting discounts and commissions, and other estimated offering expenses. Interpace has also granted the underwriters an over-allotment option to purchase up to an additional 108,000 shares. The offering is expected to close on or about Feb. 8.

Interpace said it intends to use the net proceeds for working capital, to repay debt and other liabilities, and for general corporate purposes.

Maxim Group is acting as sole book-running manager for the offering. Roth Capital Partners is serving as financial advisor.